Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7457MR)

This product GTTS-WQ7457MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7457MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11091MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ13749MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ4742MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ12960MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ8459MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ13214MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ8621MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ1031MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW